Home > Insider Trading > Filing (0001519692-23-000006)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1819790	Tarsus Pharmaceuticals Inc.	TARS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1519692	M. Leonard Greenstein	C/O Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine CA 92618	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-03-15	4,462	$0.00	38,751	No	4	M	Direct
Common Stock	Disposition	2023-03-16	313	$13.43	38,438	No	4	S	Direct
Common Stock	Disposition	2023-03-16	5,000	$13.44	33,438	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-03-15	4,462	$0.00	4,462	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,388			No	4	M	Direct

Footnotes

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs")
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.
The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.28 to $13.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each RSU represents a contingent right to receive one share of the Company's common stock.
RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service.